Tom Yates

Recent Contributions

Reply to A game-changer in TB prevention!

Aug. 4, 2018
In the UK, we routinely use three months of rifampicin/isoniazid (Rifinah) to treat LTBI.

WHO Facility Checklist

July 31, 2018
Dear colleagues, Does anyone know whether this Checklist for Periodic Evaluation of TB Infection Control in Health-Care Facilities <http://www.who.int/tb/areas-of-work/preventive-care/checklist_for_periodic_evaluation_of_tb_infection_control_in_health_facilities.pdf> is the most up to date version? The copyright is dated 2015 and it refers to documents from 2009, 2012, 2014 and 2015. If this is the most recent document, does ...

Accuracy of DST and mortality

July 20, 2018
Dear all, I thought I would share this important preprint by Matthias Egger and team... https://www.biorxiv.org/content/early/2018/07/18/370056 They found limited agreement between DST results performed locally and those performed in a reference lab. Discordance was clearly of clinical importance with patients treated with inappropriate regimens experiencing markedly higher mortality. What does ...

Reply to Simultaneous TB/HCV treatment

June 6, 2018
Hello, I don't have experience. However, I note there is now a useful looking drug interaction checker for the hepatitis drugs, run by the same people that make the Liverpool HIV drug interactions tools... https://www.hep-druginteractions.org/

Reply to HIV+ people with MDR-TB at higher risk of aminoglycoside-related hearing loss

May 22, 2018
Dear Erica, Thanks, these are valuable data. However, HIV positive people embarking on MDR treatment are at risk of many other severe adverse outcomes in addition to hearing loss. I strongly dispute the suggestion that there is a 'large body of evidence favoring the use of newer drugs such as ...


Recent Recommendations

None at this time.